BioTime (LCTX) mit Buy rating

https://www.analystratings.com/articles/...a-buy-from-h-c-wainwright/
Zu Biotime:

AMD affects more than 30 million people worldwide and approximately 1.6 million people are newly diagnosed annually in the U.S.1 It is a leading cause of vision loss in people over the age of 60 in the developed world. There are two forms of AMD: “wet AMD,” which affects only 10% of patients and “dry AMD,” which affects 90% of patients.2 Currently, there are only two FDA-approved therapies for the less common wet AMD, yet they constitute an estimated $6 billion dollar market.3

https://lineagecell.com/products-pipeline/opregen/

https://lineagecell.com/  

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral  

 

https://www.analystratings.com/articles/...peutics-lctx-cytodyn-cydy/  

https://old.nasdaq.com/de/symbol/lctx/real-time  

https://www.analystratings.com/articles/...ge-cell-therapeutics-lctx/  

https://old.nasdaq.com/de/symbol/lctx/real-time  

https://www.analystratings.com/articles/...ge-cell-therapeutics-lctx/  

https://www.benzinga.com/general/biotech/21/06/...estoration-in-mid-s